ATS 2024 Final Program

Click on the session title to view the speakers

122

MONDAY • MAY 20

9:45 Dysanapsis in Later Life: Clinical Outcomes and Host Environment Interactions 10:00 Defining Dysanapsis: Spirometry and Beyond 10:15 Omic Insights into the Origins of Dysanapsis 10:30 The Next 50 Years: Summary and Panel Discussion

9:15 Beyond Antibiotics: Unleashing the Power of Non-Antibiotic Therapies in Pneumonia Management 9:25 Harnessing the Potential of Cytokine Therapy in Pneumonia Management 9:40 Beyond Inflammation: Unveiling the Potential of Steroid Therapy in Pneumonia Management 9:55 Phage Power: Harnessing Bacteriophages for Pneumonia Treatment and Prevention 10:05 Monoclonal Antibody-Based Therapies for Bacterial Infections 10:20 Breaking the Barrier: Conquering Pathogenic Biofilms in Pneumonia 10:30 Unlocking the Potential of Therapies in Mitigating Long-Term Mortality and Cardiovascular Events Following Pneumonia

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

B10 NON-ANTIBIOTIC THERAPY FOR PNEUMONIA Assemblies on Pulmonary Infections and Tuberculosis; Clinical Problems; Nursing; Pediatrics 9:15 a.m. - 10:45 a.m. San Diego Convention Center Room 6B (Upper Level) Target Audience Scientists, clinicians (pulmonology, Infectious Disease, pediatrics, Geriatricians), public health/global health practitioners, and trainees interested in respiratory infections. Objectives At the conclusion of this session, the participant will be able to: • understand the potential of non-antibiotic therapies in the management of pneumonia and their role in combating antibiotic resistance • explore the mechanisms of action and efficacy of specific non-antibiotic treatments, such as cytokine therapy, steroid therapy, and bacteriophage therapy, in the context of pneumonia • discuss the challenges and opportunities associated with the implementation of non-antibiotic therapies in clinical practice, including considerations of safety, patient selection, and optimizing treatment outcomes Our symposium is designed to boost awareness and comprehension of non-antibiotic pneumonia treatments among healthcare professionals, researchers, and the public. We aim to spark collaboration across various fields, promoting evidence-based practice, sharing recent research, and circulating clinical guidelines. As we drive advancements and novel approaches, we’re fostering innovation and improving patient outcomes. By focusing on non-antibiotic treatments, we aim to enhance personalized interventions, thus maximizing efficacy and minimizing side effects.

CLINICAL • TRANSLATIONAL PRESIDENT SYMPOSIUM

B11 PRESIDENT'S SYMPOSIUMPASSION,

PERSEVERANCE, ANDQUANTUMLEAPS: CELEBRATING ADVANCES IN LUNG CANCER

9:15 a.m. - 10:45 a.m.

San Diego Convention Center Room 6C-F (Upper Level)

Target Audience: All attendees interested in lung cancer Objectives

At the conclusion of this session, the participant will be able to: • apply the recommendations of USPSTF for lung cancer screening and understand their limitations, risks, and benefits. • learn about the scientific basis for and new discoveries in lung cancer biomarkers and their implications for current and future applications. • improve the care of patients with lung cancer through enhanced knowledge of scientific and clinical advances in the field and their current and future applications. 9:35 Introduction 9:50 From Chest X-ray to Chest CT: 50 Years of Lung Cancer Screening Development - Ramp it Up!

ATS 2024 Conference Program • San Diego, CA